BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year [Seeking Alpha]
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: Seeking Alpha
BGE-102 achieved 86% hsCRP reduction and favorable safety in Phase 1, positioning BIOA for a pivotal Phase 2a trial in 2H 2026. BIOA holds ~$285M in cash post-raise, funding operations through 2029 and supporting multiple clinical milestones, including new obesity and ophthalmology candidates. Strategic partnerships with Eli Lilly and Novartis, plus a differentiated mechanism, offer upside, but investors should weigh high clinical and competitive risks. This idea was discussed in more depth with members of my private investing community, Haggerston BioHealth. Learn More » J Studios/DigitalVision via Getty Images Investment Overview This is my first time providing coverage of BioAge Labs ( BIOA ), a biotech company based in Emeryville, California, that completed its IPO in October 2024, raising ~$238m via the issuance of 13.23m shares priced at $18 per share. More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech,
Show less
Read more
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- BioArctic publishes the Annual Report and Sustainability Report for 2025PR Newswire
- BioArctic publishes the Annual Report and Sustainability Report for 2025PR Newswire
- BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP [Yahoo! Finance]Yahoo! Finance
- BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRPGlobeNewswire
- BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference [Yahoo! Finance]Yahoo! Finance
BIOA
Earnings
- 3/24/26 - Miss
BIOA
Sec Filings
- 4/21/26 - Form DEFA14A
- 4/21/26 - Form DEF
- 4/3/26 - Form 4
- BIOA's page on the SEC website